congress on 12 december 2013 the adapt act aims to fast track the drug development in order to combat the growing public health threat of superbugs under this act fda can approve antibiotics and antifungals needed for life threatening infections based on data from smaller clinical trials the cdc will reinforce the monitoring of the use of antibiotics that treat serious and life threatening infections and the emerging resistance and make the data publicly available the fda antibiotics labeling process susceptibility test interpretive criteria for microbial organisms or breakpoints is also streamlined to allow the most up to date and cutting edge data available to healthcare professionals under the new act congress has been urged in 2014 from several parties to aid the development of new drugs via bills such as adapt allan coukell director of drugs and medical devices at the pew charitable trusts testified in front of the house committee in a statement published by reuters that by allowing drug developers to rely on smaller datasets and clarifying fda s authority to tolerate a higher level of uncertainty for these drugs when making a risk benefit calculation adapt would make the clinical trials more feasible